Sign up to save your podcasts
Or
Share 30 Da Vinci Copycats Will Fail with John Murphy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
30 Da Vinci Copycats Will Fail with John Murphy
John Murphy left a corporate COO role to become employee number one at Virtual Incision then spent the next 14 years building MIRA, the world's first miniaturised soft tissue surgical robot.
The pitch? A little robot on the inside, instead of a big one reaching in from the outside. The journey included five alpha iterations, a 30,000-page FDA de novo submission, remote surgery experiments from the International Space Station, and raising every dollar from Midwest investors after getting zero interest from Boston or Silicon Valley.
Now advising the next generation of medtech founders, John shares the tactical, financial, and personal lessons from one of surgical robotics' longest development cycles.
Key Topics:
Why miniaturised surgical robotics could reshape remote and rural surgery
Breaking a 14-year R&D journey into financeable, executable chunks
The ISS experiment: remote surgery from 250 miles above Earth
Why Midwest investors backed Virtual Incision when the coasts wouldn't
Related Insights:
Medical devices is harder than aerospace, bio, and every other industry John's worked in
The "nuclear winter" of medtech financing and signs of a thaw
How to think about seed through Series D as clinical and regulatory milestones
Core Challenges:
Financing cycles in medtech often outlast VC fund timelines, founders must align milestones with capital strategy
Differentiation is non-negotiable: "There's 30 me-too Da Vinci players, Gary and Dave are going to win that one
The personal toll of being a startup CEO is underestimated, founders need support beyond tactics and strategy
🎧 Tune in now for hard-won lessons on building breakthrough surgical robotics, from first prototype to FDA clearance and beyond.
The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.
To learn more about Cruxx, click here.
A big thank you to our sponsors on this season of the podcast;
TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
&
KUKA is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.
KUKA provides trusted support throughout the product life cycle, from development to integration and beyond.
Find out more at kuka.com/healthcare
View all episodes
By The Crux of Medtech
5
22 ratings
John Murphy left a corporate COO role to become employee number one at Virtual Incision then spent the next 14 years building MIRA, the world's first miniaturised soft tissue surgical robot.
The pitch? A little robot on the inside, instead of a big one reaching in from the outside. The journey included five alpha iterations, a 30,000-page FDA de novo submission, remote surgery experiments from the International Space Station, and raising every dollar from Midwest investors after getting zero interest from Boston or Silicon Valley.
Now advising the next generation of medtech founders, John shares the tactical, financial, and personal lessons from one of surgical robotics' longest development cycles.
Key Topics:
Why miniaturised surgical robotics could reshape remote and rural surgery
Breaking a 14-year R&D journey into financeable, executable chunks
The ISS experiment: remote surgery from 250 miles above Earth
Why Midwest investors backed Virtual Incision when the coasts wouldn't
Related Insights:
Medical devices is harder than aerospace, bio, and every other industry John's worked in
The "nuclear winter" of medtech financing and signs of a thaw
How to think about seed through Series D as clinical and regulatory milestones
Core Challenges:
Financing cycles in medtech often outlast VC fund timelines, founders must align milestones with capital strategy
Differentiation is non-negotiable: "There's 30 me-too Da Vinci players, Gary and Dave are going to win that one
The personal toll of being a startup CEO is underestimated, founders need support beyond tactics and strategy
🎧 Tune in now for hard-won lessons on building breakthrough surgical robotics, from first prototype to FDA clearance and beyond.
The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.
To learn more about Cruxx, click here.
A big thank you to our sponsors on this season of the podcast;
TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
&
KUKA is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.
KUKA provides trusted support throughout the product life cycle, from development to integration and beyond.
Find out more at kuka.com/healthcare